Mayo Clinic | Strategic Alliance Partners

Joleen M. Hubbard, MD, discusses key survival data from the phase 1b study of the PolyPEPI1018 vaccine and the impact of these findings on continued investigations of this vaccine in metastatic colorectal cancer.

Drs Goetz and Choong discuss the potential for adjuvant endocrine therapy omission in patients with estrogen receptor–positive breast cancer who have a pathologic complete response to neoadjuvant chemotherapy.

Second-line lenvatinib may produce a survival benefit in patients with advanced hepatocellular carcinoma who have progressed on immunotherapy.

Tanios S. Bekaii-Saab, MD, FACP, expands on key data reported from the MOUNTAINEER trial, the potential effects of this regimen’s approval on the current treatment landscape, and the continued investigation of this and other targeted approaches in metastatic colorectal cancer.

Christina Wu, MD, discusses key targeted therapies under investigation in patients with colorectal cancer.

Dr Hilal discusses data with frontline ibrutinib, acalabrutinib, and zanubrutinib in chronic lymphocytic leukemia; remaining uncertainties regarding the use of BTK inhibitors to manage this disease; and how a patient’s minimal residual disease status influences their subsequent treatment options.

Konstantinos Leventakos, MD, PhD, discusses the emergence of immunotherapy and lurbinectedin as beneficial treatments in small cell lung cancer, where osimertinib fits into the non–small cell lung cancer treatment paradigm, and more.

Shaji Kumar, MD, discusses the updated data from the phase 3 MAIA trial in newly diagnosed multiple myeloma.

Dr Kumar, Dr Patel, Falbo, and Ahlstrom highlight the importance of community-based discussions regarding adverse effects in multiple myeloma, the benefits of considering the whole treatment course, and subgroup analyses from the MAIA trial.

Jeanne M. Palmer, MD, discusses a retrospective analysis of the PERSIST-1 and PAC203 trials, the symptoms that were analyzed across patient populations, and what the findings from this research indicate about the relationship between low platelet counts and symptoms such as fatigue in myelofibrosis.

Jeanne M. Palmer, MD, discusses total symptom scores in patients with myelofibrosis with thrombocytopenia.

S. Vincent Rajkumar, MD, previews his top 5 abstracts in multiple myeloma ahead of the 2022 ASH Annual Meeting.

Mojun Zhu, MD, discusses key findings from the phase 3 TOPAZ-1 trial in patients with biliary tract cancer.

Lionel Kankeu Fonkoua, MD, discusses key considerations when selecting a treatment regimen for patients with hepatocellular carcinoma.

Matthew P. Goetz, MD, discusses the impact of the phase 3 PALOMA-2 trial in estrogen receptor–positive/HER2-negative advanced breast cancer.

Prognosis, treatment outcomes, and molecular characteristics have become associated with sidedness in colorectal cancers making the distinction an essential characteristic for consideration in decison-making.

Investigators hope to add RLY-4008, the first highly selective FGFR2 inhibitor, to the growing arsenal of treatment options for patients with cholangiocarcinoma.

Matthew P. Goetz, MD, discusses the clinical significance of the phase 2 ELAINE-1 trial of lasofoxifene in patients with ESR1-mutated, estrogen receptor-positive/HER2-negative metastatic breast cancer.

Early sensitivity to FGFR inhibition has improved outcomes for patients across tumor histologies; however, kinase domain mutations limit extended efficacy for select patients including those with intrahepatic cholangiocarcinoma or urothelial cancer.

Stephen M. Ansell, MD, PhD, discusses the investigation of loncastuximab tesirine in the phase 2 LOTIS-2 trial in relapsed/refractory diffuse large B-cell lymphoma.

Matthew P. Goetz, MD, discusses the progression-free survival benefit derived with lasofoxifene in patients with ESR1-mutated, ER-positive/ HER2-negative metastatic breast cancer.

Evidence-based decisions have leveraged the use of immunotherapy combination atezolizumab plus bevacizumab for patients who receive a diagnosis of hepatocellular carcinoma.

Single-agent lasofoxifene did not produce a statistically significant improvement in progression-free survival vs fulvestrant for patients with estrogen receptor–positive, HER2-negative metastatic breast cancer harboring ESR1 mutations.

The addition of abemaciclib to a nonsteroidal aromatase inhibitor elicited an improvement in overall survival vs a nonsteroidal aromatase inhibitor alone in patients with hormone receptor–positive, HER2-negative, early-stage breast cancer.

Findings of a retrospective study demonstrated a high dosing compliance with daratumumab compared with approved indications for patients with multiple myeloma in the real-world setting.

Drs Bekaii-Saab, George, and von Mehren discuss patient-reported outcomes from the INTRIGUE trial, the rationale for a phase 1/2 study investigating DCC-3116 in patients with RAS or RAF–mutated solid tumors, and how vimseltinib may alleviate unmet needs in the tenosynovial giant cell tumors population.

Judy C. Boughey, MD, shares criteria for omission of sentinel lymph node surgery, the importance of not altering treatment based on identification of variants of uncertain significance, and the potential value of trastuzumab deruxtecan in HER2-low metastatic breast cancer.

Matthew P. Goetz, MD, discusses overall survival data with ribociclib and abemaciclib in estrogen receptor–positive, HER2-negative disease; the role of adjuvant pembrolizumab in patients with triple-negative breast cancer; and the efficacy of PARP inhibitors in earlier settings. 

Yi Lin, MD, PhD, discusses patient eligibility for CAR T-cell therapy in hematologic cancers.

At the start of his career, Weijing Sun, MD, FACP, was motivated to explore potential new treatments for gastrointestinal malignancies, and is now an internationally known GI cancer expert.